Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
InChi: InChI=1S/C39H60O12/c1-21(2)36-26(7)31(49-33(42)16-15-32(40)41)20-39(46
Smiles: OC1=CC(=CC=C1)C1C2C=CC(N=2)=C(C2=CC=C(N2)C(C2=CC(O)=CC=C2)=C2CCC(=N2)C(=C2C=CC=1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1
AMD 3465 (50 nM) totally blocks CXCL12-induced calcium mobilization
Mitiglinide calcium hydrate N 14494 The drug was developed byMitiglinide calcium hydrate is a drug for the treatment of type 2 diabetes; it is a highly selective KATP channel antagonist. IC50 value: Target: KATP channel Product information CAS Number: 207844 01 7 Molecular Weight: 353. 46 Formula: C38H54CaN2O8 Synonym: KAD 1229 calcium hydrate S 21403 calcium hydrate Chemical Name: calcium bis((2S) 4 [(3aR,7aS) octahydro 1H isoindol 2 yl] 2 benzyl 4 oxobutanoic acid) dihydrate Smiles: O. O.[Ca+2].
US$ 495.00
US$ 10837.50
US$ 9350.00
US$ 10750.00
US$ 6500.00
US$ 111302.00
US$ 16750.00
US$ 3200.00
US$ 13200.00
US$ 4650.00